AID  Vol.5 No.3 , September 2015
Analysis on Immune Tolerance and Resistance Mechanism of Cryptococcus albidus of AIDS Patients with Opportunistic Cryptococci Infection
Abstract: Objective: To explore more about the immune tolerance and drug resistance of white Cryptococci albidus in AIDS patients with opportunistic Cryptococcus infection. Methods: To analyze drug resistance of the samples of white Cryptococcus albidus extracted from opportunistic infection AIDS patients in the certain infection area from October 2011 to December 2014. Results: After analyzing two samples of Cryptococcus albidus from 885 cases with opportunistic infection, we found that one of the samples do resist to ten common antibiotics. They were fluconazole, flu-cytosine, fluconazole, caspofungin, amphotericin B, MI miconazole, terbinafine, ketoconazole and itraconazole. The other one was sensitive to voriconazole, but resistant to the rest of the drug. Two strains of bacteria were inoculated into the animals in vivo and their DNA was extracted to carry out the genotyping analysis. The results showed that different degrees of resistance gene amplification bands were found in the 10 kinds of antibiotics. Conclusion: Although there were few opportunistic infection Cryptococcus albidus in AIDS patients, it was easy to show its resistance to drugs. Therefore, great attention should be paid to it for the medical workers.
Cite this paper: Yang, X. , Su, G. and Mo, L. (2015) Analysis on Immune Tolerance and Resistance Mechanism of Cryptococcus albidus of AIDS Patients with Opportunistic Cryptococci Infection. Advances in Infectious Diseases, 5, 118-124. doi: 10.4236/aid.2015.53014.

[1]   Chen, M., Pan, W.H. and Boekhout, T. (2013) Cryptococcus gattii Infections in China: Extent of the Problem? Chinese Medical Journal, 126, 203-205.

[2]   Hong, L.X., Song, W.J., Bo, F.X., et al. (2014) Cryptococcus neoformans and Gerth Clinical Molecular Epidemiology of Cryptococcus in Shenzhen. Chinese Journal of Infectious, 32, 204-208.

[3]   Alanis, E., Macdougall, L., Kidd, S., et al. (2010) Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerging Infectious Diseases, 16, 251-257.

[4]   Kamoto, K., Hatakeyama, S., Itoyama, S., et al. (2010) Cryptococcus gattii Genotype VGIIa Infection in Man, Japan, 2007. Emerging Infectious Diseases, 16, 1155-1157.

[5]   Li, L.X., Yuan, T., Zhen, S.Y., et al. (2012) The Construction of Expression Vector and Identification in MISlGene siRNA of Cryptococcus neoformans. Chinese Journal of Mycology, 7, 17-19.

[6]   Fang, M.Y., Xian, F.Z., Wei, F., et al. (2015) Construction and Application of Cryptococcus Infection in Vitro Blood-Brain Barrier Model. Chinese Journal of Mycology, 10, 92-95.

[7]   Srinivasan, B., Kolli, A.R., Esch, M.B., et al. (2015) TEER Measurement Techniques for in Vitro Barrier Model Systems. Journal of Laboratory Automation, 20, 107-126.

[8]   Wuest, D.M., Wing, A.M. and Lee, K.H. (2013) Menbrane Configuration Optimization for a Murine in Vitro Blood-Brain Barrier Model. Journal of Neuroscience Methods, 212, 211-221.